Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.62 |
| ▸ | CA9 | Q16790 | 13/20 | 0.62 |
| ▸ | CA12 | O43570 | 12/20 | 0.62 |
| ▸ | CA1 | P00915 | 14/20 | 0.59 |
| ▸ | CA5A | P35218 | 8/20 | 0.59 |
| ▸ | CA7 | P43166 | 8/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 8/20 | 0.59 |
| ▸ | CA6 | P23280 | 6/20 | 0.59 |
| ▸ | CA4 | P22748 | 6/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.59 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.59 |
| ▸ | CA3 | P07451 | 3/20 | 0.56 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202948 | 0.85 | CA2 (0.81) | CA2CA9CA12CA1CA5A | |
| SCHEMBL21627142 | 0.77 | ALDH1A1 (0.52) | TSHRALDH1A1MAPT | |
| SCHEMBL10493509 | 0.77 | CA2 (0.68) | CA2CA9CA12CA1CA5A | |
| SCHEMBL1805283 | 0.74 | CA2 (0.65) | CA2CA9CA12CA1CA5A | |
| Sulfanilamide SCHEMBL31544839 | 0.74 | CA2 (1.00) | CA2CA9CA12CA1CA5A | |
| Sulfanilamide SCHEMBL740 | 0.74 | CA2 (1.00) | CA2CA9CA12CA1CA5A | |
| Sulfanilamide SCHEMBL30659052 | 0.74 | CA2 (1.00) | CA2CA9CA12CA1CA5A | |
| Sulfanilamide SCHEMBL2798899 | 0.74 | CA2 (1.00) | CA2CA9CA12CA1CA5A | |
| SCHEMBL24934348 | 0.72 | LMNA (0.59) | CA2CA12CA1CA7CA14 | |
| SCHEMBL1804514 | 0.72 | CA2 (0.62) | CA2CA9CA12CA1CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126118-A | Synthesis method of celecoxib | 上海应用技术大学 | 2023-11-28 | — | — | CN | disclosed |
| CN-108026110-A | Fused tricyclic compounds as kinases inhibitor | 国家公共部门基金会卡洛斯三世国家癌症研究中心(F.S.P.CNIO) | 2018-05-11 | — | — | CN | disclosed |
| US-9447037-B2 | 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yl)benzenesulfonamide as alpha 7 nAChR modulator | LUPIN LIMITED (IN) | 2016-09-20 | — | — | US | disclosed |
| US-20160107990-A1 | 4-(5-(4-CHLOROPHENYL)-2-(2-CYCLOPROPYLACETYL)-1,4-DIMETHYL-1H-PYRROL-3-YL)BENZENESULFONAMIDE AS ALPHA 7 NACHR MODULATOR | LUPIN LIMITED (IN) | 2016-04-21 | — | — | US | disclosed |
| US-8222807-B2 | Organic electroluminescence device and method of producing organic device | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222807-B2 | Organic electroluminescence device and method of producing organic device | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| US-20100090590-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND METHOD OF PRODUCING ORGANIC DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100090590-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND METHOD OF PRODUCING ORGANIC DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100045174-A1 | COMPOSITION FOR USE IN ORGANIC DEVICE, POLYMER FILM, AND ORGANIC ELECTROLUMINESCENT ELEMENT | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20090309070-A1 | COMPOSITIONS FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ORGANIC ELECTROLUMINESCENT DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090033208-A1 | FILM FORMING COMPOSITION AND ORGANIC ELECTROLUMINESCENT DEVICE | PIONEER CORPORATION (JP) | 2009-02-05 | — | — | US | disclosed |
| WO-2008138889-A2 | 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | CA2 3368/4885CA9 4460/4885CA12 4808/4885 |
| US-20160107990-A1 | 4-(5-(4-CHLOROPHENYL)-2-(2-CYCLOPROPYLACETYL)-1,4-DIMETHYL-1H-PYRROL-3-YL)BENZENESULFONAMIDE AS ALPHA 7 NACHR MODULATOR | CHRNA7, CHRNA4, CHRNE | CA2 2571/4885CA9 3588/4885CA12 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.